Mereo BioPharma had previously reported very promising Phase II data suggesting that acumapimod is an effective treatment of AECOPD, and on the back of this, has already generated significant interest from various potential partners. However, uncertainty about the route-to-market for acumapimod had hindered negotiations; with this now better understood, we expect Mereo BioPharma to soon enter more meaningful discussions with potential partners that could result in a deal by year end. Our valuation of Mereo BioPharma is currently under review, as the company is executing the proposed business combination with NASDAQ-listed OncoMed Pharmaceuticalsin (due to complete in the coming weeks). Prior to the announced combination, we valued Mereo BioPharma at £510m, or 615p/share.
16 Apr 2019
Path cleared for partnering of acumapimod (BCT-197)
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Path cleared for partnering of acumapimod (BCT-197)
- Published:
16 Apr 2019 -
Author:
Mick Cooper PhD -
Pages:
2
Mereo BioPharma had previously reported very promising Phase II data suggesting that acumapimod is an effective treatment of AECOPD, and on the back of this, has already generated significant interest from various potential partners. However, uncertainty about the route-to-market for acumapimod had hindered negotiations; with this now better understood, we expect Mereo BioPharma to soon enter more meaningful discussions with potential partners that could result in a deal by year end. Our valuation of Mereo BioPharma is currently under review, as the company is executing the proposed business combination with NASDAQ-listed OncoMed Pharmaceuticalsin (due to complete in the coming weeks). Prior to the announced combination, we valued Mereo BioPharma at £510m, or 615p/share.